医学物理学
阶段(地层学)
疾病
医学
过程(计算)
情感(语言学)
生活质量(医疗保健)
重症监护医学
计算机科学
放射治疗计划
治疗方法
梅德林
质量(理念)
平面图(考古学)
风险分析(工程)
病态的
作者
María Reig,Marco Sanduzzi‐Zamparelli,Alejandro Forner,Jordi Rimola,Joana Ferrer,Marta Burrel,Ángeles García‐Criado,Alba Díaz,Neus Llarch,Gemma Iserte,Meritxell Mollà,Robin Kate Kelley,Peter R. Galle,Vincenzo Mazzaferro,Riad Salem,Bruno Sangro,Amit G. Singal,Arndt Vogel,Ted K. Yanagihara,Carmen Ayuso
标识
DOI:10.1016/j.jhep.2025.10.020
摘要
The 2026 BCLC update incorporates recent therapeutic advances in HCC into its recommendations, while preserving simplicity. Each disease stage remains directly linked to its evidence-based first-line treatment option. The BCLC algorithm provides guidance for evaluating patient prognosis and proposes a therapeutic strategy according to the current scientific evidence. Tumour boards require structured methodologies to address clinical complexity. Beyond published evidence, decision-making should incorporate biological, psychosocial, and contextual factors that may affect morbidity, feasibility, and patient vulnerability. Such a multidimensional approach ensures treatments remain evidence-based and patient-centred. The updated clinical decision-making chapter embeds the CUSE (Complexity, Uncertainty, Subjectivity, Emotion) framework. CUSE turns unavoidable doubt into a shared, iterative process to: (i) define the therapeutic goal (survival, tumour control, quality of life, etc.); (ii) grade each option, noting evidence strength and gaps; (iii) align choices with comorbidities, feasibility, oncologic risk, and patient values and goals; and (iv) select a plan with regular check-ins as new information or needs arise.
科研通智能强力驱动
Strongly Powered by AbleSci AI